Sutton J.,Argenta 8 9 Spire Green Center |
Clark D.E.,Argenta 8 9 Spire Green Center |
Higgs C.,Argenta 8 9 Spire Green Center |
Higgs C.,Schrodinger |
And 12 more authors.
Bioorganic and Medicinal Chemistry Letters | Year: 2014
In this Letter, we present the results of a hit-finding and lead optimization programme against the EP4 receptor (EP4R). In a short time period, we were able to discover five structurally diverse series of hit compounds using a combination of virtual screening methods. The most favoured hit, compound 6, was demonstrated to be a competitive antagonist of the EP4R. Compound 73 was identified following several rounds of optimization, which centred on improving both the primary EP4R affinity and selectivity against the related EP2R as well as the aqueous solubility. This work culminated in the preparation of PGN-1531, the sodium salt of 73, which showed a marked improvement in solubility (>10 mg/mL). PGN-1531 is a potent and selective antagonist at EP4Rs in vitro and in vivo, with the potential to alleviate the symptoms of migraine that result from cerebral vasodilatation. © 2014 Elsevier Ltd. All rights reserved. Source